Skip to content

Effect of obesity factors on the dose-effect relationship of ciprofol compound alfentanil for painless gastroscopy

Effect of obesity factors on the dose-effect relationship of ciprofol compound alfentanil for painless gastroscopy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300079004
Enrollment
Unknown
Registered
2023-12-22
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless gastroscopy

Interventions

Normal group:The biased coin design (BCD) were used,the initial dose of ciprofol was set to 0.2 mg/kg and the dose gradient was 0.04 mg/kg. When movement, choking, swallowing and other reactions, seda
Overweight group:The biased coin design (BCD) were used,the initial dose of ciprofol was set to 0.2 mg/kg and the dose gradient was 0.04 mg/kg. When movement, choking, swallowing and other reactions,
Obesity group:The biased coin design (BCD) were used,the initial dose of ciprofol was set to 0.2 mg/kg and the dose gradient was 0.04 mg/kg. When movement, choking, swallowing and other reactions, sed

Sponsors

Baoding NO.1 Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients to undergo elective painless gastroscopy; 2, Age 18-65 years; 3, ASA grade ? or ?; 4, Mouth opening = 2.5 cm; 5, Normal head and neck mobility; 6, Mallampati grade? or ?; 7. Patients have fully understood the nature of the study and voluntarily participate in the trial and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. History of allergy to test drugs; 2. History of neurological diseases; 3. High risk of inhalation; 4. Expected airway difficulty; 5. Long term use of sedatives; 6. Acute upper gastrointestinal bleeding; 7. Investigators considered any conditions inappropriate to be selected for any reason.

Design outcomes

Primary

MeasureTime frame
95% effective dose;

Secondary

MeasureTime frame
Adverse effects such as bradycardia, hypotension, hypoxia, choking, body movement, and swallowing during the induction period;SpO2, HR and MAP were recorded before anesthesia (T0), 1min after injection (T1) and gastroscopy (T2);

Countries

China

Contacts

Public ContactChunguang Wang

Baoding NO.1 Central Hospital

13831253611@163.com+86 186 1778 9771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026